Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy.

Palmer S.

Curr Opin HIV AIDS. 2013 Mar;8(2):87-92. doi: 10.1097/COH.0b013e32835d80af.

PURPOSE OF REVIEW: This review will describe advances in detection and results of monitoring persistent viremia in patients on long-term suppressive therapy. In addition, the review explores the usefulness of these methods in determining the effectiveness of new HIV-1 eradication strategies in purging persistent HIV-1 reservoirs. RECENT FINDINGS: Quantification of plasma HIV-1 RNA levels remains essential for determining the success of combination antiretroviral therapy (cART) in treated patients. Recently, several new platforms with improved sensitivity for quantifying HIV-1 RNA have been developed and the application of these assays has revealed that low-level viremia persists in patients on suppressive therapy. In addition, new technological advances such as digital PCR have been proposed to increase the sensitivity of measuring and characterizing persistent HIV-1 viremia. The application of these assays will be important in determining the effectiveness of future HIV-1 eradication strategies. SUMMARY: The level of HIV-1 RNA in patient plasma remains an important marker for determining the success of cART. New sensitive assays have found that HIV-1 persists in the plasma of patients on suppressive therapy that may have implications for the clinical management of this disease and strategies for eliminating HIV-1 infection.

PMID: 23314906

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.